Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.35 |
| ▸ | ATR | Q13535 | 4/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20089716 | 0.80 | RXRA (0.37) | RXRARXRBRXRGATRCACNA1B | |
| SCHEMBL22941293 | 0.79 | CYP11B2 (0.48) | CYP11B2RXRARXRBRXRGSLC6A3 | |
| SCHEMBL31179155 | 0.77 | RXRA (0.38) | CYP11B2RXRARXRBRXRGATR | |
| SCHEMBL20116867 | 0.76 | NQO2 (0.46) | RXRARXRBRXRGATRSCN9A | |
| SCHEMBL31179070 | 0.75 | RXRA (0.47) | CYP11B2RXRARXRBRXRGATR | |
| SCHEMBL22499127 | 0.75 | RXRA (0.47) | CYP11B2RXRARXRBRXRGATR | |
| SCHEMBL22499128 | 0.75 | RXRA (0.47) | CYP11B2RXRARXRBRXRGATR | |
| SCHEMBL31179136 | 0.75 | RXRA (0.41) | CYP11B2RXRARXRBRXRGCYP4F2 | |
| SCHEMBL31178753 | 0.75 | RXRA (0.42) | CYP11B2RXRARXRBRXRGSLC6A3 | |
| SCHEMBL31093895 | 0.74 | ATR (0.36) | CYP11B2RXRARXRBRXRGATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2026-03-05 | — | — | US | disclosed |
| EP-4647424-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-11-12 | — | — | EP | disclosed |
| WO-2024181437-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | 中外製薬株式会社 | 2024-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | MYT1, NTMT1, MYL6 | CYP11B2 1599/4885RXRA 4502/4885RXRB 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.